Oncotelic Therapeutics, Inc. (OTCQB: OTLC) announced the completion of key Phase 2 objectives in its manufacturing automation initiative with TechForce Robotics, advancing commercialization of an AI-powered good manufacturing practices (GMP) manufacturing services platform at SAPU Bio, the company’s 45%-owned sterile injectable cGMP manufacturing joint venture. The Phase 2 deployment expands the capabilities of Oncotelic’s proprietary PDAOAI platform across sterile manufacturing operations, electronic batch records, GMP workflow execution, cleanroom monitoring and autonomous materials movement.
The integrated platform combines PDAOAI with TechForce’s autonomous robotic systems to support intelligent pharmaceutical manufacturing. According to the company, this creates potential opportunities in software licensing, automation deployment, manufacturing partnerships and technology-enabled contract development and manufacturing services. Oncotelic plans to demonstrate the platform at the BIO International Convention 2026 in San Diego as it pursues broader commercialization efforts within the pharmaceutical manufacturing sector.
Oncotelic Therapeutics is a clinical-stage biopharmaceutical company focused on oncology and immunotherapy products, addressing high-unmet-need cancers and rare pediatric indications with late-stage therapeutic candidates. In addition to its directly owned drug pipeline, Oncotelic benefits from a portfolio of inventions by its CEO, Dr. Vuong Trieu, who has filed over 500 patent applications and holds 75 issued patents. The company also leverages its proprietary AI-enabled PDAOAI platform, which supports research, biomarker discovery, and regulatory processes through advanced data analysis and knowledge integration.
Beyond its internal programs, Oncotelic licenses and co-develops select drug candidates through strategic partnerships and joint ventures. The company currently owns a 45% interest in GMP Bio, a joint venture advancing a pipeline of therapeutic candidates. For more information, visit https://nnw.fm/j1n43.
